lncRNA EGOT Is the Marker of HPV Infection and a Prognostic Factor for HNSCC Patients

作者：Tomasz Kolenda, Piotr Białas, Kacper Guglas, Maciej Stasiak, Joanna Kozłowska-Masłoń, Karina Tylkowska, Anna Zapłata, Paulina Poter, Marlena Janiczek-Polewska, Patrycja Mantaj, Paulina Gieremek, Urszula Kazimierczak, Anna Przybyła, Katarzyna Regulska, Beata Jadwiga Stanisz, Ewa Leporowska, Andrzej Adam Mackiewicz, Jacek Mackiewicz, Joanna Kazmierska, Zefiryn Cybulski, Anna Teresiak · 发表于：Biomedicines · 年份：2025 · DOI：10.3390/biomedicines13040798 · 被引用次数：5 · 研究领域：Cancer-related molecular mechanisms research、RNA modifications and cancer、Cholangiocarcinoma and Gallbladder Cancer Studies

Background: High-risk human papillomavirus (HPV) contributes to oropharyngeal cancers through mechanisms involving the deregulation of host cell functions by oncoproteins E6 and E7. Changes in the epigenome, particularly involving long non-coding RNAs (lncRNAs), are crucial for understanding HPV-related carcinogenesis. Methods: This study aimed to analyze the expression levels of lncRNAs in HPV-related head and neck squamous cell carcinoma (HNSCC) to determine their biological and clinical significance, addressing the current gap in clinically validated biomarkers for early screening and therapeutic interventions. Results: The study highlights the significant overexpression of the EGOT gene in HPV-positive HNSCC samples, suggesting its potential as a marker to distinguish between HPV-negative and HPV-positive cases. Furthermore, high EGOT expression correlates with better overall survival (OS) and indicates possible resistance to therapy, making it a valuable prognostic factor. Conclusions: These findings underscore the potential of incorporating EGOT expression analysis in clinical practice for improved patient stratification and treatment outcomes in HNSCC.